Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HER2 in solid tumors: more than 10 years under the microscope; where are we now?

Future oncology (London, England) - 1 Jun 2014

Martin Vittoria, Cappuzzo Federico, Mazzucchelli Luca, Frattini Milo

Abstract excerpt

HER2 is a well-recognized mediator of the cancerogenic process. It is dysregulated in a wide range of solid tumors, mainly via protein overexpression and/or gene amplification, thus making HER2 an attractive target for tailored treatment. The anti-HER2 therapy trastuzumab was approved for the treatment of HER2-positive metastatic breast cancer patients more than 10 years ago. Since then, trastuzumab and other...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antineoplastic Agents
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Targeted Therapy

Share to Mutation

Share to Neoplasms

Share to Receptor, ErbB-2

Source

Identifiers

PMID: 25052756
DOI: 10.2217/fon.14.19

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HER2 in solid tumors: more than 10 years under the microscope; where are we now?PMID 25052756Read ↗

A Comprehensive Review of HER2 in Cancer Biology and TherapeuticsSemantic proximity Read ↗

A Comprehensive Review of HER2 in Cancer Biology and TherapeuticsSemantic proximity Read ↗

Molecular Pathways and Mechanisms of HER2 in Cancer TherapySemantic proximity Read ↗

Molecular Targeting the Human Epidermal Growth Factor Receptor-2 (HER2) Genes Across Various CancerSemantic proximity Read ↗

Molecular Targeting of the Human Epidermal Growth Factor Receptor-2 (HER2) Genes across Various CancersSemantic proximity Read ↗

The human epidermal growth factor receptor 2 (HER2)Semantic proximity Read ↗

HER2 aberrations in cancer: implications for therapy.Semantic proximity Read ↗

Advances in EGFR/HER2-directed clinical research on breast cancer.Semantic proximity Read ↗

A review of HER2 overexpression and somatic mutations in cancers.Semantic proximity Read ↗

HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists.Semantic proximity Read ↗

Targeting ERBB2/HER2 genetic alterations: an expanding therapeutic opportunity in gastrointestinal cancers.Semantic proximity Read ↗

HER2: Biology, Detection, and Clinical ImplicationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.